Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14347MR)

This product GTTS-WQ14347MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14347MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3445MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ2506MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ6312MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ15698MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ14582MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ6711MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ15511MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ6701MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DNIB0600A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW